Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study.

James W Smithy Hannah L Kalvin Fiona D Ehrich Ronak H Shah Matthew J Adamow Vladislav Raber Colleen A Maher Jenna Kleman Deborah A G McIntyre Alexander N Shoushtari Allison Betof Warner Margaret K Callahan Parisa Momtaz Omar Eton Suresh G Nair Jedd D Wolchok Paul B Chapman Michael F Berger Katherine S Panageas Michael A Postow

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Adaptively dosed nivo-ipi responses are durable and resemble historical data for conventional nivo-ipi. Baseline IL-6 and ctDNA changes during treatment warrant further study as biomarkers of nivo-ipi response.

Keyphrases

electronic health record
machine learning